Meeting
2023 ASCO Annual Meeting
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
Authors
Apostolia Maria Tsimberidou
University of Texas MD Anderson Cancer Center, Houston, TX
Apostolia Maria Tsimberidou , David J. Vining , Sukeshi Patel Arora , Sofia de Achaval , Jeffrey Larson , Carrie Cartwright , Rony Avritscher , Imran Alibhai , Ahmed Omar Kaseb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03195699
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3018)
DOI
10.1200/JCO.2023.41.16_suppl.3018
Abstract #
3018
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.
First Author: Apostolia Maria Tsimberidou
Poster
2019 ASCO Annual Meeting
A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.
First Author: Safi Shahda
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study to evaluate the safety and efficacy of TTI‑101 as monotherapy and in combination in advanced hepatocellular carcinoma.
First Author: Farshid Dayyani
Poster
2023 ASCO Annual Meeting
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
First Author: Mirella Nardo